ClinicalTrials.gg
RecruitingNCT05819684Updated Jun 21, 2024

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

A Phase 1 interventional study of SHR-4602 for injection in Advanced Solid Tumor, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
133
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Advanced/unresectable or solid tumor with expression or mutation that is to or intolerable with standard treatment, or for which no standard treatment is available;
  2. At least one based on v1.1 criteria;
  3. PS score: 0-1 points;
  4. Expected survival period ≥ 3 months;
  5. Adequate organ function;
  6. Must take one medically approved measure;
  7. Patients voluntarily joined the study and signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients with known or hepatic encephalopathy;
  2. Suffering from peripheral neuropathy;
  3. History of lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or suspected to have these diseases by imaging at screening period;
  4. Patients with any active, known or suspected disorder;
  5. With known severe allergic reactions to any other monoclonal antibodies;
  6. Patients with symptomatic ascites or pleural effusion requiring paracentesis and drainage, or patients who have undergone ascites or pleural effusion drainage within 2 weeks before the first dose;
  7. Patients with other currently or within the past 5 years;
  8. Uncontrolled cardiac diseases or symptoms;
  9. With known hereditary or acquired bleeding (e.g., coagulopathy) or a tendency to clot (e.g., hemophiliacs);
  10. Patients with other potential factors that may affect the study results.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose escalation

    Drug: SHR-4602 for injection

  • Experimental
    Part 2: PK expansion

    Drug: SHR-4602 for injection

  • Experimental
    Part 3: efficacy expansion

    Drug: SHR-4602 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Time frame: From Day 1 to 90 days after last dose

  2. Maximum tolerated dose (MTD)

    Time frame: From Day 1 to 21 days after first dose

  3. Dose Limiting Toxicities (DLT)

    Time frame: From Day 1 to 21 days after first dose

  4. Recommended Phase 2 dose (RP2D)

    Time frame: From Day 1 to 90 days after last dose

Secondary outcomes

  1. PK parameters of SHR-4602 for Injection: Cmax

    Time frame: the date of first dose to 30 days after last dose

  2. PK parameters of SHR-4602 for Injection: AUC0-t

    Time frame: the date of first dose to 30 days after last dose

  3. PK parameters of SHR-4602 for Injection: Tmax

    Time frame: the date of first dose to 30 days after last dose

  4. PK parameters of SHR-4602 for Injection: T1/2

    Time frame: the date of first dose to 30 days after last dose

  5. ADA

    Anti-drug antibody, Immunogenicity of SHR-4602 for Injection

    Time frame: the date of first dose up to 90 days after last dose

  6. ORR

    Objective Response Rate, Efficacy endpoints of SHR-4602 for Injection,As assessed by RECIST v1.1

    Time frame: the date of first dose up to 90 days after last dose

  7. DCR

    Disease control rate, Efficacy endpoints of SHR-4602 for Injection,As assessed by RECIST v1.1

    Time frame: the date of first dose up to 90 days after last dose

  8. DOR

    Duration of response, Efficacy endpoints of SHR-4602 for Injection,As assessed by RECIST v1.1

    Time frame: the date of first dose up to 90 days after last dose

  9. PFS

    Progression Free Survival, Efficacy endpoints of SHR-4602 for Injection,As assessed by RECIST v1.1

    Time frame: the date of first dose up to 90 days after last dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for May 2025, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 19, 2023
StartActual
Apr 18, 2023
Primary completionEst.
May 30, 2025
CompletionEst.
May 30, 2026
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05819684
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Apr 18, 2023
Primary completion
May 30, 2025 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Jun 21, 2024

Study contacts

Xin Shi
Contact
xin.shi.xs3@hengrui.com
0518-82342973
Wenjie Xin
Contact
wenjie.xin@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-4602

Start the discussion